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The method was applied to a high-cost innovation in oncology
currently under development in ﬁve European countries, carbon
ion radiotherapy. RESULTS: 138 potential factors identiﬁed, 116
ﬁnal factors were analysed and regrouped into 9 areas. The
Principal Components Analysis between countries 1 and 2, and
between 4 and 5, showed proximity between the costs of equip-
ment and the cost of buildings. A large variation was observed
using the Euclidean metric between countries 1 and 2, especially
for working time, and between countries 4 et 5 for the use
of personnel resources. On the opposite, a low distance was
observed between countries 2 and 4 for treatment capacity, and
between countries 2 and 3 for technology availability and costs
of personnel. CONCLUSION: Using this method we could assess
the generalisability of the cost of carbon ion radiotherapy, and
we identiﬁed factors and areas that limited this generalisability.
This study also showed the necessity to integrate recommenda-
tions in order to increase the generalisability of economic evalu-
ations in health care.
MC2
BAYESIAN MODELING OF RESOURCE USE ALONGSIDE
MULTINATIONAL RANDOMISED CLINICALTRIALS
Gauthier A1, Manca A2,Anton SF3, Dewberry H4
1i3 Innovus, Uxbridge, Middlesex, UK, 2University of York,York, UK,
3Boehringer-Ingelheim, Ridgeﬁeld, CT, USA, 4Boehringer Ingelheim
Limited, Bracknell, Berkshire, UK
OBJECTIVES: Most cost-effectiveness analyses conducted
alongside multinational randomized controlled clinical trials
(RCTs) are carried out applying the unit costs from the country
of interest to each resource item with the objective of estimating
total health care by treatment group. An alternative is to model
health care resource use (HCRU) directly rather than expressed
in monetary units. This study aimed to model HCRU collected
alongside RCTs, accounting for their speciﬁc distributions and
the hierarchical structure of the data. METHODS: The analysis
was conducted using data from multinational RCTs enrolling
approximately 2000 patients suffering from a chronic disease.
For each HCRU, appropriate distribution functions were identi-
ﬁed based on the deviance of the univariate model (including
treatment effect only). Standard models were extended to the
Bayesian multi-level models (MLM) settings, whereby covariates
at different levels (patient, centre and country) were introduced
as predictors. RESULTS: Depending on the treatment group,
69% to 71% of patients had no GP visits. The Poisson distribu-
tion under-estimated the proportion of zeros by 18%, whereas
the negative binomial (NB) and zero-inﬂated Poisson (ZIP)
provided good matches. The greater ﬂexibility of ZIP models
provided signiﬁcantly better ﬁt than NB. ZIP was the best distri-
bution to model health care resource contacts and the zero
inﬂated Poisson overdispersed (ZIPO) function was best repre-
senting concomitant medications treatment days. GP visits pre-
sented the highest heterogeneity between countries (9% of the
variance was explained by the country effect) and this was well
captured by the MLMs. CONCLUSION: Misspeciﬁcation of
statistical models may result in biased parameters and misleading
inference. This study proposed the development of ZIP and ZIPO
MLMs to model HCRU alongside RCTs. To obtain more precise
estimates, multivariate analyses of HCRU could be conducted
and other sources of evidence could be used additionally, external
to the clinical studies.
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OBJECTIVES: The purpose of this study was to investigate the
development of an incremental willingness to pay curve (IWTPC)
using parameters obtained from a discrete choice experiment
(DCE). METHODS: The DCE was structured around a novel
genetic technology that identiﬁes genetic causes of developmental
delay (DD). The DCE included three alternatives. The ﬁrst two
alternatives differed on three attributes: number of children
receiving a genetic diagnosis, time waiting for results, and cost.
The third alternative was an opt-out option to allow for non-
demanders. A mixed logit (MXL) behavioural model was speci-
ﬁed to incorporate preference heterogeneity, and hierarchical
Bayes (HB) was employed to estimate the joint posterior of
parameter partworths. The opt-out parameter was assumed to
follow a normal distribution, a truncated normal was given to
number of children diagnosed and waiting time, and the log
normal distribution was assumed for cost. The HB procedures
employed allow for the direct estimation of each individual’s
parameter estimates, which are transformed into an incremental
willingness to pay (WTP) value. Under certain assumptions, the
IWTPC represents the incremental WTP that each individual in
society has for the technology under a given scenario. RESULTS:
A total of 796 respondents from the general public were recruited
using a research ﬁrm in British Columbia, Canada. Each respon-
dent completed 16 choice questions. The parameter estimates
revealed a considerable amount of preference heterogeneity,
which indicated that the mean incremental WTP estimate might
not accurately represent society’s WTP. Individual WTP ranged
from $28 to $12,000 for an increase in 14 children identiﬁed to
have a genetic cause of DD and a 1-week reduction in waiting
time. Fifty-one percent of respondents had an incremental WTP
of at least $1041 for the scenario. CONCLUSION: Using the
joint posterior of preference partworths, the IWTPC is a prom-
ising tool to characterize the value of a health care good.
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OBJECTIVES: The increasing use of full economic evaluations
has lead to the development of various instruments to assess their
quality. In addition to the much used British Medical Journal
(BMJ) check-list, two new instruments were recently developed:
the Consensus Health Economic Criteria (CHEC) list and the
Quality of Health Economic Studies (QHES) instrument. The
purpose of this study was to compare these three instruments as
quantitative tools to measure the quality of economic evalua-
tions. The analysis was performed through a systematic review of
economic evaluations of the surgical treatment of obesity.
METHODS: Quality of 9 selected studies was assessed indepen-
dently by two health economist experts. Rater 1 repeated the
analysis after 8 weeks. The spearman rank correlation coefﬁcient
was used at time 1 and 2 to compare the instruments, and for
each instrument, the intraclass correlation coefﬁcient (ICC(3,1))
to assess test-retest reliability between time 1 and 2. For each
instrument, the interrater agreement was estimated at two levels:
comparison of the total score of each article by the ICC(2,1) and
comparison of results per item by kappa values. RESULTS:
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